When was Tavanta founded?

Tavanta was founded in 2011 and raised its 1st funding round 1 year after it was founded.

Where is Tavanta located?

Tavanta is headquartered in King Of Prussia, United States.

How many employees does Tavanta have?

As of Jun 30, 2026, the latest employee count at Tavanta is 5.

Is Tavanta a funded company?

Tavanta is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 16, 2012.

When was the latest funding round of Tavanta?

Tavanta's latest funding was a $***** Seed round on Jan 16, 2012, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $564M in funding in 2026 to date.

Where does Tavanta rank among its competitors?

Tavanta ranks 1690th amongst 4472 active competitors, of which 1231 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Tavanta?

Tavanta's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Tavanta - 2026 Company Profile, Team, Funding & Competitors

Company Details

Tavanta develops a drug for debilitating multiple medical conditions. It is a clinical-stage pharmaceutical company involve in the development of a diverse drug pipeline. The company is in phase 3 for drug candidate TAVT-45 targeting Prostate Cancer, phase 2 for TAVT-119 (Chronic Anal Fissures), TAVT-124 is in the early stage of phase 2 for Multiple Sclerosis, and in phase 1 for TAVT-124 and TAVT-135; for Autoimmune Indications and Cystic Fibrosis. The company uses an HT Matrix screening platform for the development of peptide conjugate development.

Website: www.tavanta.com
Email ID: *****@tavanta.com
Phone Number: +1 **********

Key Metrics

Founded Year

2011

Location

King Of Prussia, United States

Stage

Seed

Total Funding

$4.05M in 1 round

Latest Funding Round

Seed, Jan 16, 2012, $*****

Investors

Savitr Capital & 1 more

Ranked

1690^th among 4472 active competitors

Employee Count

5 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3305 more

View Tavanta's full profile

Tavanta is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TAVANTA THERAPEUTICS, INC. CIN: 851292307 , United States, Active	Dec 31, 1999	-	12 (As on Dec 31, 2022)	-

Tavanta has raised a total funding of $4.05M over 1 round. Its latest funding round was a Seed round on Jan 16, 2012 for $*****. 1 investor participated in its latest round. Tavanta has 2 institutional investors.

Here is the list of recent funding rounds of Tavanta:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 16, 2012	5444106	Seed	3620762	1428326	4930941	9314861

Access funding benchmarks and valuations. Sign up today!

View details of Tavanta's funding rounds and investors

Tavanta's employee count trend

Tavanta has 5 employees as of Jun 26. Here is Tavanta's employee count trend over the years:

Uncover Tavanta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tavanta include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Tavanta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
1690th	Tavanta 2011, King Of Prussia (United States), Seed	Developer of drug for debilitating multiple medical conditions	$4.05M	Savitr Capital, DBH Group	34/100